有效控制体液免疫, 提高移植物长期存活率

于立新

doi:10.3969/j.issn.1674-7445.2014.06.001

有效控制体液免疫, 提高移植物长期存活率

doi: 10.3969/j.issn.1674-7445.2014.06.001

于立新^,

510515 广州, 南方医科大学南方医院器官移植科

基金项目:

国家自然科学基金 81350009, 81141058, 81070594

广东省科技计划项目 2012B031800470

详细信息

通讯作者:
于立新，教授、主任医师、博士研究生导师。毕业于第一军医大学，现任南方医科大学(原第一军医大学)南方医院器官移植科主任。享受国务院特殊津贴，中央保健局特聘专家。兼任中国医师协会器官移植医师分会第一届委员会副会长、中华医学会器官移植学会常务委员、全国肾移植组副组长、广东省器官移植学会主任委员、广东省医学会理事会理事、中国透析移植学会委员、广东省泌尿外科学会委员。兼任《器官移植》杂志常务编委，《中华外科杂志》、《中华泌尿外科杂志》等多家杂志编委。长期从事泌尿外科以及腹部器官移植基础与临床研究，完成肾移植4 000余例，肝移植100余例，多器官联合移植20余例，并成功完成了亚洲首例肝胰联合移植以及亚洲最高龄肝肾联合移植。发表学术论文200余篇，主编器官移植学专著2部，主持研究10项省级、军队重点课题基金，10余项国家、省级自然科学基金，曾获国家科技进步二等奖2项、省部级科技进步一等奖4项以及军队、省级科技进步二等奖5项。荣获第三届中国医师奖及广东省丁颖科技奖。 Email:yulixin@medmail.com.cn

中图分类号: R617
计量
- 文章访问数: 29
- HTML全文浏览量: 35
- PDF下载量: 8
- 被引次数: 0
出版历程
- 收稿日期: 2014-09-12
- 网络出版日期: 2021-01-19
- 刊出日期: 2014-11-15

摘要

- 器官移植 /
- 供者特异性抗体 /
- 体液免疫 /
- 自身抗体

HTML全文

参考文献(19)

[1]	Terasaki PI, Ozawa M. Predicting kidney graft failure by HLA antibodies: a prospective trial[J].Am J Transplant, 2004, 4(3):438-443. doi: 10.1111/ajt.2004.4.issue-3
[2]	薛武军, 郑瑾. 重视组织配型和供者特异性抗体监测在肾移植中的重要作用[J]. 器官移植, 2014, 5(2):63-65. http://www.organtranspl.com/browse/detail/cat/29/id/216 Xue WJ, Zheng J. Important role of tissue matching and donor specific antibody monitoring in renal transplantation[J]. Organ Transplant, 2014, 5(2):63-65. http://www.organtranspl.com/browse/detail/cat/29/id/216
[3]	Lachmann N, Terasaki PI, Budde K, et al. Anti-human leukocyte antigen and donor-specificantibodies detected by luminex posttransplant serve as biomarkers for chronic rejection of renal allografts[J]. Transplantation, 2009, 87(10):1505-1513. doi: 10.1097/TP.0b013e3181a44206
[4]	Terasaki PI, Cai J. Human leukocyte antigen antibodies and chronic rejection: from associationto causation[J]. Transplantation, 2008, 86(3):377-383. doi: 10.1097/TP.0b013e31817c4cb8
[5]	Kohei N, Hirai T, Omoto K, et al. Chronic antibody-mediated rejection is reduced by targeting B-cell immunity during an introductory period[J]. Am J Transplant, 2012, 12(2):469-476. doi: 10.1111/j.1600-6143.2011.03830.x
[6]	Everly MJ, Everly JJ, Susskind B, et al. Bortezomib provides effective therapy for antibody-and cell-mediated acute rejection[J]. Transplantation, 2008, 86(12):1754-1761. doi: 10.1097/TP.0b013e318190af83
[7]	Perry DK, Burns JM, Pollinger HS, et al. Proteasome inhibition causes apoptosis of normal human plasma cells preventing alloantibody production[J]. Am J Transplant, 2009, 9(1):201-209. http://cn.bing.com/academic/profile?id=1506252195&encoded=0&v=paper_preview&mkt=zh-cn
[8]	Sberro-Soussan R, Zuber J, Suberbielle-Boissel C, et al. Bortezomib as the sole post-renaltransplantation desensitization agent does not decrease donor-specific anti-HLA antibodies[J].Am J Transplant, 2010, 10(3):681-686. doi: 10.1111/ajt.2010.10.issue-3
[9]	Woodle ES, Alloway RR, Girnita A. Proteasome inhibitor treatment of antibody-mediated allograft rejection[J]. Curr Opin Organ Transplant, 2011, 16(4):434-438. doi: 10.1097/MOT.0b013e328348c0e5
[10]	Oura T, Yamashita K, Suzuki T, et al. Long-term hepatic allograft acceptance based on CD40 blockade by ASKP1240 in nonhuman primates[J]. Am J Transplant, 2012, 12(7):1740-1754. doi: 10.1111/j.1600-6143.2012.04014.x
[11]	Tedder TF. CD19: a promising B cell target for rheumatoid arthritis[J]. Nat Rev Rheumatol, 2009, 5(10):572-577. doi: 10.1038/nrrheum.2009.184
[12]	Nagorsen D, Kufer P, Baeuerle PA, et al. Blinatumomab: a historical perspective[J]. Pharmacol Ther, 2012, 136(3):334-342. doi: 10.1016/j.pharmthera.2012.07.013
[13]	Stegall MD, Diwan T, Raghavaiah S, et al. Terminal complement inhibition decreases antibody-mediated rejection in sensitized renal transplant recipients[J]. Am J Transplant, 2011, 11(11):2405-2413. doi: 10.1111/ajt.2011.11.issue-11
[14]	Biglarnia AR, Nilsson B, Nilsson T, et al. Prompt reversal of a severe complement activation by eculizumab in a patient undergoing intentional ABO-incompatible pancreas and kidney transplantation[J]. Transpl Int, 2011, 24(8):e61-e66. doi: 10.1111/tri.2011.24.issue-8
[15]	Dalmasso AP, Platt JL. Prevention of complement-mediated activation of xenogeneic endothelial cells in an in vitro model of xenograft hyperacute rejection by C1 inhibitor[J].Transplantation, 1993, 56(5):1171-1176. doi: 10.1097/00007890-199311000-00024
[16]	Terasaki PI, Ozawa M, Castro R. Four-year follow-up of a prospective trial of HLA and MICA antibodies on kidney graft survival[J]. Am J Transplant, 2007, 7(2):408-415. doi: 10.1111/ajt.2007.7.issue-2
[17]	Fukami N, Ramachandran S, Saini D, et al. Antibodies to MHC class Ⅰ induce autoimmunity:role in the pathogenesis of chronic rejection[J]. J Immunol, 2009, 182(1):309-318. doi: 10.4049/jimmunol.182.1.309
[18]	Nath DS, Basha HI, Mohanakumar T. Antihuman leukocyte antigen antibody-induced autoimmunity:role in chronic rejection[J]. Curr Opin Organ Transplant, 2010, 15(1):16-20. doi: 10.1097/MOT.0b013e3283342780
[19]	Iwata T, Philipovskiy A, Fisher AJ, et al. Anti-type V collagen humoral immunity in lung transplant primary graft dysfunction[J]. J Immunol, 2008, 181(8):5738-5747. doi: 10.4049/jimmunol.181.8.5738